# US 2021/0332035 A1 · 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332035 A1
- Document ID: US20210332035A1
- Status: Published application
- Kind: A1
- Application number: 17/268,914
- Filed: 2019-08-15
- Published: 2021-10-28
- Earliest claimed: 2018-08-17
- Assignees: Shanghai Leado Pharmatech Co. Ltd.
- Applicants: Shanghai Leado Pharmatech Co. Ltd.
- Inventors: Youxin WANG; Zhenlin QU; Lingling ZHANG
- Web page: https://patentgrep.com/patent/US20210332035A1

## CPC

- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/381: having five-membered rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 17/04: Antipruritics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are a 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof. Specifically disclosed is a compound or a pharmacologically acceptable salt thereof or a prodrug thereof. The compound has the structure of formula I. The compound or the pharmacologically acceptable salt thereof or the prodrug thereof has excellent inhibition to transient receptor potential (TPR) channel proteins, and has good therapeutic effect on diseases related to the TPR channel proteins.

## Claims

### Claim at position 1

-22. (canceled)

### Claim 23

A method for (a) inhibiting a transient receptor potential channel protein (TRPA1); or (b) preventing and/or treating a disease related to transient receptor potential channel protein (TRPA1); which comprises administering a compound, or a pharmaceutically acceptable salt, or a prodrug thereof to a subject in need;
wherein the compound has a structure of formula Z:
wherein,
ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, or a substituted or unsubstituted 5-7 membered heteroaromatic ring;
R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
X is an oxygen atom, sulfur atom or nitrogen atom;
R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
n is 1, 2 or 3;
“*” means that the configuration of the compound is racemate;
wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound of formula Z is selected from the following group:

### Claim 25 (depends on 23)

The method of claim 23, wherein the disease related to transient receptor potential channel protein (TRPA1) is selected from the group consisting of pain, epilepsy, inflammation, respiratory disorder, pruritus, urinary tract disorder, inflammatory bowel disease, and a combination thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the pain is selected from the group consisting of acute pain, inflammatory pain, visceral pain, neurogenic pain, muscle fiber pain, headache, neuralgia, mixed pain, cancer-induced pain, and a combination thereof.

### Claim 27

A method for (a) inhibiting transient receptor potential channel protein (TRP); or (b) preventing and/or treating a disease related to transient receptor potential channel protein (TRP); which comprises administering a compound, or a pharmaceutically acceptable salt, or a prodrug thereof to a subject in need;
wherein the compound has a structure of formula I:
wherein,
ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, o a substituted or unsubstituted 5-7 membered heteroaromatic ring;
R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
X is an oxygen atom, sulfur atom or nitrogen atom;
R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
n is 1, 2 or 3;
wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.

### Claim 28 (depends on 27)

The method of claim 27, wherein the compound comprises one or more features selected from the following group:
A is a substituted or unsubstituted 5-7 membered carbocyclic ring or a 5-7 membered heteroaromatic ring;
X is S or O;
R1 and R2 are each independently hydrogen or substituted or unsubstituted C1-C3 alkyl; and/or
R3 is hydrogen, halogen, or substituted or unsubstituted C1-C6 alkyl.

### Claim 29 (depends on 27)

The method of claim 27, wherein the compound comprises one or more features selected from the following group:
A is a substituted or unsubstituted 5-membered carbocyclic ring, a substituted or unsubstituted 6-membered carbocyclic ring, or a substituted or unsubstituted furan ring;
R1 and R2 are each independently hydrogen, methyl or ethyl;
R3 is hydrogen atom, chlorine or a methyl; and/or
n is 1.

### Claim 30 (depends on 27)

The method of claim 27, wherein the compound is selected from the following group:

### Claim 31 (depends on 27)

The method of claim 27, wherein the transient receptor potential channel protein (TRP) is TRPA1.

### Claim 32 (depends on 27)

The method of claim 27, wherein the disease related to transient receptor potential channel protein (TRP) is selected from the group consisting of pain, epilepsy, inflammation, respiratory disorder, pruritus, urinary tract disorder, inflammatory bowel disease, and a combination thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the pain is selected from the group consisting of acute pain, inflammatory pain, visceral pain, neurogenic pain, muscle fiber pain, headache, neuralgia, mixed pain, cancer-induced pain, and a combination thereof.

### Claim 34

A compound, or a pharmaceutically acceptable salt, or a prodrug thereof, wherein the compound has a structure of formula Z:
wherein,
ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, or a substituted or unsubstituted 5-7 membered heteroaromatic ring;
R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
X is an oxygen atom, sulfur atom or nitrogen atom;
R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
n is 1, 2 or 3;
“*” means that the configuration of the compound is racemate;
wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.

### Claim 35 (depends on 34)

The compound of claim 34, wherein the compound is selected from the following group:

### Claim 36

A compound, or a pharmaceutically acceptable salt, or a prodrug there of, wherein the compound has a structure of formula I:
wherein,
ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, or a substituted or unsubstituted 5-7 membered heteroaromatic ring;
R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
X is an oxygen atom, sulfur atom or nitrogen atom;
R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
n is 1, 2 or 3;
wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.

### Claim 37 (depends on 36)

The compound of claim 36, wherein the compound comprises one or more features selected from the following group:
A is a substituted or unsubstituted 5-7 membered carbocyclic ring or a 5-7 membered heteroaromatic ring;
X is S or O;
R1 and R2 are each independently hydrogen or substituted or unsubstituted C1-C3 alkyl; and/or
R3 is hydrogen, halogen, or substituted or unsubstituted C1-C6 alkyl.

### Claim 38 (depends on 36)

The compound of claim 36, wherein the compound comprises one or more features selected from the following group:
A is a substituted or unsubstituted 5-membered carbocyclic ring, a substituted or unsubstituted 6-membered carbocyclic ring, or a substituted or unsubstituted furan ring;
R1 and R2 are each independently hydrogen, methyl or ethyl;
R3 is hydrogen atom, chlorine or a methyl; and/or
n is 1.

### Claim 39 (depends on 36)

The compound of claim 36, wherein the compound is selected from the following group:

### Claim 40 (depends on 34)

A pharmaceutical composition which comprises a compound of claim 34, or a pharmaceutically acceptable salt, or a prodrug thereof; and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 36)

A pharmaceutical composition which comprises a compound of claim 36, or a pharmaceutically acceptable salt, or a prodrug thereof; and a pharmaceutically acceptable carrier.

### Claim 42 (depends on 36)

A intermediate of formula II or III
wherein X, A, R3 and n are as defined in claim 36.
